However, the therapeutic activities on the same BRAF class I mutations in CRC patients are limited, likely caused by a rapid feedback activation of the upstream RTK and the resultant restoration of uncontrolled signaling in the pathway, a phenomenon which is specifically observed in CRC with BRAF mutations [44,45,46]. The gene discussed is BRAF; the disease is colorectal carcinoma.